UNSPSC 51401561: Chlordiazepoxide hydrochloride

This classification denotes a benzodiazepine with the molecular formula C16H14ClN3O.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier MFM6K1XWDK, chemically known as 7-chloro-n-methyl-5-phenyl-3h-1,4-benzodiazepin-2-amine 4-oxide but more generally known as chlordiazepoxide hydrochloride, which bears US NIH Compound Identifier 2712. European Medicines Agency schedules Chlordiazepoxide hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01213MIG.

UNSPSC 51401561 Chlordiazepoxide hydrochloride is a Commodity code that nominally describes a specific benzodiazepine pharmaceutical, but recent state and local procurement activity under this code shows little alignment with that narrow scope. The three recent opportunities posted under or tagged to this code actually solicit naloxone and drug deactivation systems, therapeutic pharmacy initiative services, and generic multi-source pharmaceuticals and over-the-counter products — none of which are chlordiazepoxide hydrochloride specifically. The mismatch suggests either miscoding in the state and local procurement systems or that this code is being used as a catch-all for pharmaceutical purchasing that does not map cleanly to the commodity's definition. State and local health and human services departments, county public health agencies, and cooperative purchasing alliances are the issuing bodies present in the available records.

Recent activity spans Florida, Texas, and Minnesota. Seminole County, Florida posted IFB 60459723LAS in June 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to its Community Health Building, due July 26, 2023. The Texas Health and Human Services Commission issued RFI HHS0017013 in April 2026 to gather vendor capabilities for a direct-to-manufacturer prescription program outside traditional pharmacy benefit manager channels. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) released RFP S1070000015802 in January 2026 for generic multi-source pharmaceuticals and OTC products to supply state and local government facilities across participating states including Oregon, with proposals due March 26, 2026 and contract effectiveness July 1, 2026. The code shows limited recent relevant activity when confined to chlordiazepoxide hydrochloride specifically, making this a low-priority category for vendors specializing in that compound unless broader pharmaceutical supply relationships are the actual business objective.